Streetbeat News

Regulatory

MSFT

Microsoft's President and Vice-chairman, Brad Smith, has called for human control over artificial intelligence (AI) to prevent its weaponization. He emphasized the need for new laws and regulations to ensure safety breaks in AI technology. This comes amid global tech leaders warning about the risks posed by AI, comparing it to the risk of nuclear warfare. A report by Goldman Sachs anticipated that generative AI could impact up to 300 million jobs globally, but Smith reassured that AI is a tool supplementing human work, not replacing it.

Portfolio Pulse from Benzinga Neuro

August 29, 2023 | 9:38 am

ALVO

Alvotech has received approval from the Egyptian Drug Authority to manufacture and distribute AVT02 (Adalimumab), a biosimilar for Humira, under the name Adalimumab-EVA. This drug is indicated for rheumatoid arthritis and several other inflammatory diseases.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 9:02 am

HALO

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the approval of Roche's Tecentriq SC, which uses Halozyme's ENHANZE drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency in Great Britain. The technology allows for subcutaneous delivery, reducing the delivery time from 30-60 minutes to approximately seven minutes. The drug will be available for certain types of lung, bladder, breast, and liver cancer.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 8:53 am

TSLA

Elon Musk has announced plans to integrate the rebranded Twitter, now known as X, into Tesla vehicles. This has sparked both excitement and concern, with safety advocates raising questions about the potential for distracted driving. The announcement came in response to a Tesla user's query about watching X videos on a Tesla. While some users welcomed the idea, others expressed concerns about the potential for accidents due to distraction.

Portfolio Pulse from Ananya Gairola

August 29, 2023 | 7:55 am

VALN

Valneva's Chikungunya vaccine has entered regulatory review after Health Canada accepted its license application. This is a significant step towards the vaccine's approval and distribution in Canada.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 6:35 am

RHHBF

RHHBY

RHHVF

Roche's drug Evrysdi has received approval from the European Commission for the treatment of babies under two months old with Spinal Muscular Atrophy. This approval could potentially increase Roche's market share in the European pharmaceutical market.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 6:25 am

BMY

The FDA has approved Bristol Myers Squibb's Reblozyl for initial anemia treatment in low- to intermediate-risk myelodysplastic syndromes. This approval could potentially increase the company's market share in the pharmaceutical industry.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 6:21 am

HCM

HUTCHMED's drug Savolitinib has been granted Breakthrough Therapy Designation in China for the treatment of gastric cancer. This could potentially accelerate the drug's development and review process.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 6:13 am

BVN

Buenaventura has submitted an updated mine plan for its Uchucchacua Mine, with the anticipation of resuming activities on September 1, 2023.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 6:09 am

EWG

VGK

Germany's GfK Consumer Climate for September is reported at -25.5, which is lower than the estimated -24.3 and the prior -24.6.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 6:06 am